Program
Epoetin Alfa
Also written as “epoetin alfa”, “Epoetin alfa” and “Epoetin Hospira”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Acquired Immunodeficiency Syndrome · Neoplasms, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 660 open or running | phase 4since Sep 13, 2005 | May 9, 2002 | none ahead |
| Ortho Biotech Products, L.P. | 100 open or running | phase 4since Apr 14, 2006 | Jul 19, 2005 | none ahead |
| Novartis | 70 open or running | phase 4since Feb 29, 2008 | Feb 29, 2008 | none ahead |
| Azidus Brasil | 60 open or running | phase 3since Sep 26, 2012 | Nov 3, 2011 | none ahead |
| Ortho Pharmaceuticals | 60 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pfizer | 60 open or running | phase 3since Nov 2, 2011 | Jul 23, 2010 | none ahead |
| Amgen | 30 open or running | phase 4since Oct 3, 2012 | Jun 30, 2005 | none ahead |
| Bio Sidus | 30 open or running | phase 4since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| 3SBio | 20 open or running | phase 4since Aug 10, 2015 | Aug 10, 2015 | none ahead |
| Ortho Biotech | 20 open or running | phase 4since Nov 17, 2006 | Nov 17, 2006 | none ahead |
| incepta-pharmaceuticals-ltd | 10 open or running | phase 3since May 24, 2025 | May 24, 2025 | none ahead |
| Merck | 10 open or running | phase 2since Jun 18, 2009 | Jun 18, 2009 | none ahead |
| nanogen-pharmaceutical-biotechnology-joint-stock-company | 11 open or running | phase 1since Mar 26, 2025 | Mar 26, 2025 | Dec 2026phase 1 · NCT06919861 |
| r-w-johnson-pharmaceutical-research-institute | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| sports-medicine-research-and-testing-laboratory | 10 open or running | early phase 1since Jul 28, 2019 | Jul 28, 2019 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 3since Dec 22, 2019 | Dec 22, 2019 | none ahead |
Also a collaborator on its studies: Hexal, Navitas Life Sciences, Blau Farmaceutica and Ortho Biotech Clinical Affairs.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Mar 24, 2006.
- Jul 25, 20124 phase 1 studies in HealthyAzidus Brasil · NCT01685333, NCT01664221, NCT01664195 and 1 more
- Sep 21, 2012Phase 3 study in AnemiaNovartis · NCT01693029 · 435 enrolled · United States
- Sep 26, 2012Phase 3 study in Renal Insufficiency, ChronicAzidus Brasil · NCT01695759 · 92 enrolled · Brazil
- Oct 3, 2012Phase 4 study in AnemiaAmgen · NCT01737879 · 41 enrolled · United States
- Sep 11, 2014Phase 4 study in Renal Insufficiency, ChronicAmgen · NCT02253654 · 216 enrolled · United States, Puerto Rico
- Jul 20, 2015Phase 3 study in Renal Insufficiency, ChronicPfizer · NCT02504294 · 432 enrolled · United States, Puerto Rico
- Aug 10, 20153SBio’s first study: phase 4 study in Renal AnaemiaNew to 3SBio3SBio · NCT02522975 · 16 enrolled · Thailand
- Oct 26, 2016Phase 3 study in Renal Anemia3SBio · NCT02947438 · 207 enrolled · Russian Federation, Thailand
- Nov 11, 2016Phase 1 study in AnemiaBio Sidus · NCT03822884 · 24 enrolled
- Jul 12, 2019Phase 3 study in AnemiaBio Sidus · NCT04036253 · 43 enrolled · Argentina, Paraguay
- Jul 28, 2019sports-medicine-research-and-testing-laboratory’s first study: early phase 1 study in Healthy AthletesNew to sports-medicine-research-and-testing-laboratorysports-medicine-research-and-testing-laboratory · NCT04073849 · 24 enrolled · United States
- Dec 22, 2019Zydus Lifesciences’ first study: phase 3 study in Chronic Kidney Disease Stage 5 on DialysisNew to Zydus LifesciencesZydus Lifesciences · NCT04215120 · 392 enrolled · India
- Mar 26, 2025nanogen-pharmaceutical-biotechnology-joint-stock-company’s first study: phase 1 study in Pharmacokinetics and Pharmacodynamics in Healthy VolunteersNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06919861 · 44 planned
- May 24, 2025incepta-pharmaceuticals-ltd’s first study: phase 3 study in HealthyNew to incepta-pharmaceuticals-ltdincepta-pharmaceuticals-ltd · NCT07025681 · 56 enrolled · Bangladesh
Ahead
- Dec 2026Primary completion: phase 1 study in Pharmacokinetics and Pharmacodynamics in Healthy Volunteersnanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06919861
TargetBeta
“Erythropoietin receptor agonist”ChEMBL 37, by rule
Studies
The newest 60 of 117 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07025681Healthy · Bangladesh | 3 | Completed | incepta-pharmaceuticals-ltd | Sep 23, 2025 | 56 |
| NCT06919861Pharmacokinetics and Pharmacodynamics in Healthy Volunteers | 1 | Not yet recruiting | nanogen-pharmaceutical-biotechnology-joint-stock-company | Dec 2026 | 44 |
| NCT04215120Chronic Kidney Disease Stage 5 on Dialysis · India | 3 | Completed | Zydus Lifesciences | Sep 2, 2021 | 392 |
| NCT04073849Healthy Athletes · United States | Early 1 | Completed | sports-medicine-research-and-testing-laboratory | Nov 15, 2020 | 24 |
| NCT04036253Anemia · Argentina, Paraguay | 3 | Completed | Bio Sidus | Jun 15, 2021 | 43 |
| NCT03822884Anemia | 1 | Completed | Bio Sidus | Sep 2016 | 24 |
| NCT02947438Renal Anemia · Russian Federation, Thailand | 3 | Completed | 3SBio | Oct 9, 2021 | 207 |
| NCT02522975Renal Anaemia · Thailand | 4 | Terminated | 3SBio | Jun 2019 | 16 |
| NCT02504294Renal Insufficiency, Chronic · United States, Puerto Rico | 3 | Completed | Pfizer | Jul 2, 2016 | 432 |
| NCT02253654Renal Insufficiency, Chronic · United States, Puerto Rico | 4 | Completed | Amgen | Apr 27, 2016 | 216 |
| NCT01737879Anemia · United States | 4 | Terminated | Amgen | Mar 2013 | 41 |
| NCT01695759Renal Insufficiency, Chronic · Brazil | 3 | Terminated | Azidus Brasil | Dec 2014 | 92 |
| NCT01693029Anemia · United States | 3 | Completed | Novartis | May 2014 | 435 |
| NCT01685359Healthy · Brazil | 1 | Completed | Azidus Brasil | Oct 31, 2013 | 80 |
| NCT01685333Healthy · Brazil | 1 | Completed | Azidus Brasil | Oct 31, 2013 | 28 |
| NCT01664221Healthy · Brazil | 1 | UNKNOWN | Azidus Brasil | Oct 2013 | 80 |
| NCT01664195Healthy · Brazil | 1 | UNKNOWN | Azidus Brasil | Oct 2013 | 28 |
| NCT01628120Kidney Failure, Chronic · United States | 3 | Completed | Pfizer | Feb 13, 2015 | 170 |
| NCT01628107Kidney Failure, Chronic · United States, Puerto Rico | 3 | Completed | Pfizer | Jan 2, 2015 | 406 |
| NCT01576341Renal Insufficiency, Chronic · Germany, Italy, Poland and more | 3 | Completed | Novartis | Oct 2014 | 417 |
| NCT03572647Renal Insufficiency, Chronic · Brazil | 1 | Completed | Azidus Brasil | Nov 2012 | 40 |
| NCT01473420Kidney Failure, Chronic · United States | 3 | Completed | Pfizer | Feb 28, 2014 | 320 |
| NCT01473407Renal Insufficiency, Chronic · United States, Puerto Rico | 3 | Completed | Pfizer | Feb 11, 2014 | 612 |
| NCT01381809Myelodysplastic Syndromes · Bulgaria, France, Germany and more | 3 | Completed | Johnson & Johnson | Jan 2015 | 130 |
| NCT01374373Anemia · Argentina | 4 | Completed | Bio Sidus | Nov 2014 | 30 |
| NCT01394991Anemia | 4 | Completed | Johnson & Johnson | Sep 2009 | 504 |
| NCT01170078Kidney Failure, Chronic · United States | 1 | Completed | Pfizer | Jan 2011 | 107 |
| NCT00924781Anemia | 2 | Terminated | Merck | Apr 2010 | 39 |
| NCT00869856Anemia · Bulgaria, France, Germany and more | 3 | Withdrawn | Novartis | Aug 2009 | 0 |
| NCT00711958Anemia · Germany, Romania | 3 | Completed | Novartis | Jul 2005 | 114 |
| NCT00701714Anemia · Austria, Bulgaria, Czechia and more | 3 | Terminated | Novartis | Jul 2009 | 337 |
| NCT00695396Myelodysplastic Syndromes | 3 | Terminated | Johnson & Johnson | Jan 2010 | 25 |
| NCT00666835Anemia · Austria, Germany | 3 | Completed | Novartis | Jan 2006 | 478 |
| NCT00641589Renal Insufficiency, Chronic | 1 | Completed | Johnson & Johnson | 40 | |
| NCT00632125Renal Insufficiency, Chronic · Austria, Bulgaria, France and more | 4 | Completed | Novartis | Mar 2010 | 1,695 |
| NCT00524407Anemia | 4 | Completed | Ortho Biotech | 273 | |
| NCT00495378Neoplasms | 4 | Terminated | Ortho Biotech Products, L.P. | 25 | |
| NCT00495365Anemia | 4 | Terminated | Ortho Biotech Products, L.P. | 8 | |
| NCT00446602Myelodysplastic Syndromes | 2 | Withdrawn | Johnson & Johnson | 0 | |
| NCT00446576Anemia | 3 | Completed | Johnson & Johnson | 176 | |
| NCT00440557Anemia · United States, Puerto Rico | 3 | Completed | Johnson & Johnson | Feb 2008 | 375 |
| NCT00440466Anemia · United States | 3 | Completed | Johnson & Johnson | Mar 2009 | 430 |
| NCT00401869Anemia | 4 | Completed | Ortho Biotech | 289 | |
| NCT00388336Anemia | 2 | Completed | Johnson & Johnson | 57 | |
| NCT00386152Neoplasms · United States | 2 | Terminated | Johnson & Johnson | Mar 2008 | 235 |
| NCT00364455Carcinoma | 3 | Completed | Johnson & Johnson | 56 | |
| NCT00364260Anemia | 3 | Completed | Johnson & Johnson | 172 | |
| NCT00350519Hemostasis, Surgical | 4 | Terminated | Johnson & Johnson | Feb 2008 | 37 |
| NCT00350090Anemia | 3 | Terminated | Ortho Biotech Products, L.P. | 98 | |
| NCT00341055Anemia | 3 | Completed | Johnson & Johnson | 69 | |
| NCT00338468Anemia | 4 | Terminated | Ortho Biotech Products, L.P. | 13 | |
| NCT00338416Neoplasms | 2 | Completed | Johnson & Johnson | 115 | |
| NCT00338299Anemia | 2 | Completed | Johnson & Johnson | 51 | |
| NCT00338000Kidney Failure, Chronic | 4 | Completed | Johnson & Johnson | 292 | |
| NCT00337948Anemia | 2 | Completed | Johnson & Johnson | 129 | |
| NCT00337935Renal Insufficiency, Chronic | 2 | Completed | Johnson & Johnson | Jul 2009 | 157 |
| NCT00317902Anemia | 4 | Completed | Ortho Biotech Products, L.P. | 292 | |
| NCT00315484Anemia | 4 | Completed | Ortho Biotech Products, L.P. | 358 | |
| NCT00312871Anemia | 4 | Terminated | Johnson & Johnson | 217 | |
| NCT00307814Anemia | 2 | Completed | Ortho Biotech Products, L.P. | 519 |
How it is read
Names in the registry
- “epoetin alfa”, 47 entries
- “Epoetin alfa”, 33 entries
- “Epoetin Alfa”, 11 entries
- “Epoetin Hospira”, 5 entries
- “Erythropoietin alfa”, 4 entries
Codes read as this program: HX575.
Conditions, from the studies’ own filings
- Anemia, 73 studies
- Renal Insufficiency, Chronic, 9 studies
- Kidney Failure, Chronic, 7 studies
- Acquired Immunodeficiency Syndrome, 7 studies
- Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.